Want to see JP:7079 full AI Analyst Report?
WDB coco Co., Ltd. (7079) AI Stock Analysis
WDB coco Co., Ltd.
(TSE/TYO:7079)
WDB coco Co., Ltd. earns a score of 78, reflecting a favorable investment profile. The most compelling factor is its deep undervaluation, with a P/E below 1 and a solid dividend yield. The company's balance sheet is pristine, with minimal debt and strong equity, providing financial flexibility. While revenue and cash flow have softened recently, profitability remains healthy. Technical indicators are neutral but supportive, with the stock trading above key long-term moving averages. Overall, the stock appears attractively priced with moderate upside potential.
WDB coco Co., Ltd. (7079) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 6.13B
- Dividend Yield
- 3.73%
- Average Volume (3M)
- 1,729
- Price to Earnings (P/E)
- 0.9
- Beta (1Y)
- 0.24
- Revenue Growth
- -11.16%
- EPS Growth
- -21.80%
- Country
- Japan
- Employees
- 516
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Specialty Business Services
WDB coco Co., Ltd. Business Overview & Revenue Model
Company Description
WDB coco Co., Ltd. offers specialized contractual services to pharmaceutical companies throughout Japan. The firm plays a crucial role in advancing pharmaceuticals and medical devices, with a particular focus on safety information management, support...
How the Company Makes Money
null
WDB coco Co., Ltd. Financial Statement Overview
Summary
Revenue declined 9.2% in the latest fiscal year, breaking a multi-year growth trend, but profitability remains healthy with gross margin of 35.5% and net margin of 14.1%. The balance sheet is exceptionally strong with minimal leverage (debt-to-equity 1.7%) and robust equity. Cash flow decreased but free cash flow conversion remained high at 91.5%. Overall, the company maintains a solid financial foundation despite near-term headwinds.
Income Statement
65PositiveBalance Sheet
95Very PositiveCash Flow
70Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 54.02B | 4.82B | 5.33B | 4.60B | 4.07B | 3.62B |
| Gross Profit | 18.29B | 1.71B | 2.07B | 1.93B | 1.58B | 1.44B |
| EBITDA | 9.54B | 1.01B | 1.36B | 1.31B | 1.12B | 981.71M |
| Net Income | 6.54B | 679.31M | 912.90M | 857.83M | 743.63M | 647.70M |
Balance Sheet | ||||||
| Total Assets | 261.84B | 5.70B | 5.60B | 4.67B | 3.67B | 3.14B |
| Cash, Cash Equivalents and Short-Term Investments | 176.04B | 3.76B | 3.48B | 2.66B | 2.00B | 1.89B |
| Total Debt | 2.20B | 80.41M | 29.81M | 27.12M | 24.32M | 33.52M |
| Total Liabilities | 52.39B | 921.26M | 1.30B | 1.10B | 866.02M | 994.57M |
| Stockholders Equity | 209.45B | 4.78B | 4.30B | 3.56B | 2.80B | 2.15B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 521.82M | 1.10B | 753.84M | 469.46M | 719.72M |
| Operating Cash Flow | 0 | 570.54M | 1.10B | 772.20M | 517.49M | 747.90M |
| Investing Cash Flow | 0 | -80.53M | -88.33M | -91.82M | -302.97M | -60.48M |
| Financing Cash Flow | 0 | -207.03M | -195.83M | -110.94M | -101.21M | -79.11M |
WDB coco Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7079, the sentiment is Negative. The current price of 2565.00 is below the 20-day moving average (MA) of 2572.40, below the 50-day MA of 2574.00, and below the 200-day MA of 2596.93, indicating a bearish trend. The MACD of -8.43 indicates Positive momentum. The RSI at 43.14 is Neutral, neither overbought nor oversold. The STOCH value of 38.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7079.
WDB coco Co., Ltd. Peers Comparison
Overall Rating
- JP:707978Outperform
JP:489250Neutral
JP:453946.5Neutral
JP:488342Neutral
JP:458239Underperform
JP:458639Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:7079 | 78Outperform | JPY 6.13B | 0.94 | ― | 3.73% | -11.16% | -21.80% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4892 | 50Neutral | JPY 5.64B | -6.87 | ― | ― | 364.72% | 18.43% |
| JP:4539 | 47Neutral | JPY 5.47B | -44.12 | ― | 3.30% | 0.31% | -194.72% |
| JP:4883 | 42Neutral | JPY 3.18B | -1.17 | ― | ― | ― | -5.66% |
| JP:4582 | 39Underperform | JPY 3.72B | -0.48 | ― | ― | -30.58% | 6.93% |
| JP:4586 | 39Underperform | JPY 3.29B | -3.30 | ― | ― | 167.44% | 49.38% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:7079 | WDB coco Co., Ltd. | 2550.00 | -7.42 | -0.29% | |
| JP:4539 | Nippon Chemiphar Co., Ltd. | 1515.00 | -100.80 | -6.24% | |
| JP:4582 | Symbio Pharmaceuticals Limited | 44.00 | -71.00 | -61.74% | |
| JP:4586 | Medrx Co., Ltd. | 47.00 | -82.00 | -63.57% | |
| JP:4883 | Modalis Therapeutics Corporation | 28.00 | -47.00 | -62.67% | |
| JP:4892 | Cyfuse Biomedical K.K. | 559.00 | -26.00 | -4.44% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026